Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Shulian Shang"'
Autor:
Achim Berthele, Michael Levy, Dean M. Wingerchuk, Sean J. Pittock, Shulian Shang, Adrian Kielhorn, Minying Royston, Guido Sabatella, Jacqueline Palace
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundCumulative damage from multiple relapses in neuromyelitis optica spectrum disorder (NMOSD) is associated with poor health-related quality of life (HRQoL) and long-term disability in patients positive for anti-aquaporin 4 antibodies (AQP4+).
Externí odkaz:
https://doaj.org/article/7dcd6b20c6ed44b39cb3c1f119ab5c3b
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 11 (2018)
Background: No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing–rem
Externí odkaz:
https://doaj.org/article/8dc73721ee4e4953a23109e4e4cc0c15
Autor:
Scott D. Newsome, Thomas F. Scott, Douglas L. Arnold, Gereon Nelles, Serena Hung, Yue Cui, Shulian Shang, Maria L. Naylor, Marcelo Kremenchutzky
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 11 (2018)
Background: ADVANCE was a phase III trial of the efficacy and safety of subcutaneous peginterferon beta-1a 125 µg every 2 or 4 weeks in patients with relapsing-remitting multiple sclerosis (RRMS). ATTAIN was a 2-year extension study of ADVANCE. The
Externí odkaz:
https://doaj.org/article/0d6383108a324594a228068074ed26f7
Autor:
Paru Patrawalla, Angeliki Kazeros, Linda Rogers, Yongzhao Shao, Mengling Liu, Maria-Elena Fernandez-Beros, Shulian Shang, Joan Reibman
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e44540 (2012)
Identification and characterization of asthma phenotypes are challenging due to disease complexity and heterogeneity. The Severe Asthma Research Program (SARP) used unsupervised cluster analysis to define 5 phenotypically distinct asthma clusters tha
Externí odkaz:
https://doaj.org/article/177dde87fff4495f9c8e4d697732836f
Publikováno v:
Journal of Probability and Statistics, Vol 2012 (2012)
The false discovery proportion (FDP), the proportion of incorrect rejections among all rejections, is a direct measure of abundance of false positive findings in multiple testing. Many methods have been proposed to control FDP, but they are too conse
Externí odkaz:
https://doaj.org/article/c8f9c7e12f824a958491799561412475
Autor:
Chanh Huynh, Laura Poliseno, Miguel F. Segura, Ratna Medicherla, Adele Haimovic, Silvia Menendez, Shulian Shang, Anna Pavlick, Yongzhao Shao, Farbod Darvishian, John F. Boylan, Iman Osman, Eva Hernando
Publikováno v:
PLoS ONE, Vol 6, Iss 11 (2011)
Externí odkaz:
https://doaj.org/article/dc1081e009b54ef385af8dca07316e3f
Autor:
Chanh Huynh, Laura Poliseno, Miguel F Segura, Ratna Medicherla, Adele Haimovic, Silvia Menendez, Shulian Shang, Anna Pavlick, Yongzhao Shao, Farbod Darvishian, John F Boylan, Iman Osman, Eva Hernando
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e25264 (2011)
Several reports have demonstrated a role for aberrant NOTCH signaling in melanoma genesis and progression, prompting us to explore if targeting this pathway is a valid therapeutic approach against melanoma. We targeted NOTCH signaling using RO4929097
Externí odkaz:
https://doaj.org/article/9d30d0ca44aa4f2587ae02ce7501142d
Publikováno v:
Sunday, April 23.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::087ad88d2da786af5337f156a82a3457
https://doi.org/10.1212/wnl.0000000000202990
https://doi.org/10.1212/wnl.0000000000202990
Autor:
Eva Hernando, Iman Osman, Yongzhao Shao, Farbod Darvishian, Russell Berman, Richard Shapiro, Anna Pavlick, Shulian Shang, Daniel J. Lackaye, Avital Gaziel-Sovran, Lisa Koetz, Judy Zhong, Doug Hanniford
Supplementary Figure S2. This figure depicts brain metastatsis-free and overall survival, as plotted kaplan-meier survival curves, of high- vs low-risk patients (determined by the miRNA signature + stage model) for patients stratified by stage at dia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0b909430d9d5d14bc63bd272cd7380
https://doi.org/10.1158/1078-0432.22458140.v1
https://doi.org/10.1158/1078-0432.22458140.v1
Autor:
Eva Hernando, Iman Osman, Yongzhao Shao, Farbod Darvishian, Russell Berman, Richard Shapiro, Anna Pavlick, Shulian Shang, Daniel J. Lackaye, Avital Gaziel-Sovran, Lisa Koetz, Judy Zhong, Doug Hanniford
Purpose: Brain metastasis is the major cause of mortality among patients with melanoma. A molecular prognostic test that can reliably stratify patients at initial melanoma diagnosis by risk of developing brain metastasis may inform the clinical manag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac7b559f37e2892ef1b8d9c22906ae21
https://doi.org/10.1158/1078-0432.c.6523844
https://doi.org/10.1158/1078-0432.c.6523844